Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Guard vs Ruxolitinib for SR-aGVHD
NCT04934670Phase 3Terminated
- Sponsor
- Xenikos
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Immunotoxins
- Countries
- 9
01
Overview
A Phase 3 trial of T-Guard in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Xenikos. Started Jun 2022; status: terminated.
02
Drugs
T-Guard
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04934670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04934670.